Glaxosmithkline Share News (GSK)
GSK Share
GSK Share
GSK Share
GSK Share
GSK
GSK Share
GSK Level 2
GSK Live
GSK Broker
GSK Directors
GSK Financial
GSK
GSK Short
GSK
Last checked at -
Big insurance companies want Martin Wheatley, Chief Executive of the Financial Conduct Authority, to resign after the watchdog sent their shares into freefall by making a misleading announcement about an industry probe, the Sunday Times said. The Association of British Insurers is expected to write
Read more
LONDON, March 30 (Reuters) - GlaxoSmithKline plans to make new investments in additional factories and drug research in Africa, its chief executive said on Sunday, as the pharmaceuticals group broadens its bet on promising emerging markets. Andrew Witty said the continent was important for
Read moreWASHINGTON, March 30 (Reuters) - An experimental heart drug being developed by GlaxoSmithKline, which failed the main goal of a Phase III study of patients with chronic but well-treated heart disease, showed signs of potential benefit, the trial's co-leader said Sunday. The results presente
Read more
LONDON (Alliance News) - GlaxoSmithKline PLC said Friday that it had acquired full ownership of its Indonesian Consumer Healthcare business for IDR465 billion, equivalent to GBP24.6 million, and sold its non-core brand and manufacturing facility in the country. The company bought the remain
Read moreLONDON, March 28 (Reuters) - GlaxoSmithKline is betting more on Indonesia by taking full control of its consumer healthcare unit in the country, underscoring a drive by the drugmaker to build up its presence in fast-growing emerging markets. The move, announced on Friday, mirrors the Britis
Read moreBy Freya Berry LONDON, March 28 (Reuters) - Buyout firms are finding it harder to take part in mergers and acquisitions as the lure of stronger equity markets persuades more funds seeking to exit assets to try their luck with a public share sale or turn to cash-rich corporate buyers.
Read more* NICE to look at "wider societal impact" of new drugs * Move may mean more positive recommendations in future * NICE CEO says firms must offer NHS "very best price" * Cancer campaigners fear less money for end-of-life care (Adds further reaction from cancer charity) By
Read more* All retail supplies recalled in U.S. and Puerto Rico * European sales of Alli unaffected by move * Company investigations ongoing (Adds background on drug, detail on reported tampering, further GSK comment) By Ben Hirschler LONDON, March 27 (Reuters) - GlaxoSmithKline
Read more* Ebola virus one of most deadly known in humans * 62 dead in suspected Ebola outbreak in Guinea - WHO * Drug investment scant due to likely lack of return * U.S. government funds research due to bioweapon fears By Kate Kelland, Health and Science Correspondent LONDO
Read moreLONDON, March 27 (Reuters) - GlaxoSmithKline is recalling all supplies of its non-prescription weight-loss drug Alli in the United States and Puerto Rico, the company said on Thursday, after reports that some bottles had been tampered with. The British group, which believes that some suppli
Read moreLONDON (Alliance News) - NASDAQ-listed Myland Inc said Thursday that it has won its breach of contract case against UK pharmaceutical giant GlaxoSmithKline PLC. The jury of the United States District Court for New Jersey decided that Glaxo owes Mylan USD106.7 million in damages, over charge
Read moreCANONSBURG (Alliance News) - Mylan Inc. said Thursday that, after a trial in the US District Court for the District of New Jersey, a jury returned a verdict in favour of Mylan in its breach of contract lawsuit against GlaxoSmithKline relating to Paroxetine Hydrochloride Extended-release or ER Tab
Read moreLONDON (Alliance News) - GlaxoSmithKline PLC Thursday announced a new research collaboration with the European Bioinformatics Institute and the Wellcome Trust Sanger Institute, to harness 'big data' and genome sequencing to improve the success rate for discovering new medicines. The three w
Read more* NICE to look at "wider societal impact" of new drugs * Move may mean more positive recommendations in future * But NICE CEO says firms must offer "very best price" By Ben Hirschler LONDON, March 27 (Reuters) - British healthcare cost agency NICE is to take a broader view
Read more* GSK links with Sanger Institute, European Bioinformatics * New centre focused on target validation for new drugs * Latest example of pre-competitive collaboration in R&D By Ben Hirschler LONDON, March 27 (Reuters) - GlaxoSmithKline is linking with two top bioscience cent
Read more
Last checked at